by Government contain details of sales turnover;

(b) if so, what are the basis of stating that sales turnover is not monitored; and

(c) since all the companies have furnished the details at the time of promulgation of DPCO, 1987 what are the reasons for which the details of sales turnover of major brands like Dilosyn, Benadryl, Evion, Berin, Celin DPT etc. have not been furnished?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) to (c) Form 2 is required to be submitted in the case of scheduled formulations only. Form 4 is required to be submitted in the case of new packs of Non Scheduled formulations introduced during the period of 6 months from Jan. to June or July to Dec. as the case may be or in the case of non-scheduled formulations packs prices of which are revised durig the said period. Form 6 is meant for determining the profitability of the drug companies in formulation activity. Sales turn-over of individual formulations is not monitored in any of the cases.

Prices of tetracycline formulations

3281. SHRI M. KADHARSHA: Will the Minister of INDUSTRY be pleased to state:

(a) hat are the names of the various Tetracyclines which were the subject matter of litigation in the Supreme Court and what was the production of each from the date of litigation to the date of promulgation of DPCO, 1987;

(b) what were the prices of formulations charged by the company and those which were approved by Government along with the production of each formulation, yearwise;

(c) at what rate the recovery was made in respect of each bulk drug and each formulation; and

(d) whether the production of each of the bulk drugs and formulations is monitored?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) and (d) The production of Tetracycline bulk drug monitored by the Department for the years 1982-83 to 1985-86 is given below:

Year	Production (Tonnes) Total	Production by M/s. Cyanamid Ltd.
1982-83	209.14	8.91
1983-84	208.54	2.19
1984-85	227.04	11.10
1985-86	227.39	10.50

(b) The details of prices of formulations charged by the company are quite voluminous. The time and efforts required for collection of these details will not be commensurate with the results likely to be achieved.

(c) The amount recoverable has been calculated with reference to the prices charged by the company and the prices fixed by the Government in respect of formulations.

Recovery of DPEA dues

3282. SHRI JASWANT SINGH:
SHRI JAGESH DESAI:

Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 641 given in the Rajya Sabha on the 2nd May, 1988 and state:

(a) what are the reasons for keeping the job of recovery under the Drug Prices Eualisation Account on to itself and not getting it done from the BICP or Ministry of Finance;

(b) whether it is a fact that relaxations and concessions have been given to the drug companies so as to minimise the liability; and

(c) whether Government will submit the full details to a committee of Members of Parliament for examination?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO) (a) Department of Chemicals & Petro-Chemicals administers Drugs (Prices Control) Order. However, representatives of BICP is also associated with the Committee.

(b) No, Sir.

(c) Does not arise.

Price of Isoxuprine range formulations

3283. SHRI JASWANT SINGH:
SHRI JAGESH DESAI:

Will the Minister of INDUSTRY be pleased to state:

(a) what is the sales turnover of Isoxuprine, Flucionolone Acetonide, Polymixin Glipizide, Phenformin Hcl and Chlorpropamide as per ORG which is subscribed from out of Government funds during 1986 and 1987;

(b) whether it is a fact that more than 80 per cent of the production and distribution of these drugs is controlled by one or two companies;

(c) if so, by when price control on these products would be imposed;

(d) what were the approved prices of leading brands of these products under DPCO, 1979 and at present; and

(e) whether it is a fact that their prices have substantially gone up?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) Retail store audit report ORG does not give sales turnover and provides only All India Estimates of Retail Sales of Pharmaceuticals through the trade channel covering around 175 Companies and these estimates are based on purchase records maintained by 650 retail chemists spread out all over India. The retails sales estimates given in this report represent the purchases made by retail chemists alone, off-take of pharmaceuticals by non retail chemists are not covered in this report.

(b) No, Sir.

(c) Does not arise.

(d) The required details are quite voluminous and are not readily available. The time and efforts required for collecting the same will not be commensurate which the results likely to be achieved.

(e) As per the provision of DPCO, 1987 the manufacturers of non-scheduled medicines are free to revise the prices.

TA/DA expenditure of IDPL and HAL Directors

3284. SHRI JASWANT SINGH:
SHRI JAGESH DESAI:

Will the Minister of INDUSTRY be pleased to state:

(a) what amount has been spent by IDPL and HAL on the TA/DA of the Board of Directors during the last two years; and

(b) what amount has been spent on each of the Government Directors and what facilities were extended to such Directors during the above period?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) and (b) The requisite information is being collected and will be laid on the Table of the House.

Use of cars by Bengal Immunity

3285. SHRI JASWANT SINGH:
SHRI JAGESH DESAI:

Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that Bengal Immunity's bill on use of cars in Delhi is very high as such cars are offered to Government officers; and

(b) what was the expenditure of this Company on cars and other conveyance in Delhi during the last two years;